BRIEF-Lantheus Announces FDA Acceptance of New Drug Application for MK-6240

Reuters
Oct 28, 2025
BRIEF-Lantheus Announces FDA Acceptance of New Drug Application for MK-6240

Oct 28 (Reuters) - Lantheus Holdings Inc LNTH.O:

  • LANTHEUS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR MK-6240, A PET IMAGING AGENT TARGETING TAU IN ALZHEIMER’S DISEASE

  • LANTHEUS HOLDINGS INC - FDA SETS PDUFA TARGET DATE FOR AUGUST 13, 2026

Source text: ID:nGNX5GpcMg

Further company coverage: LNTH.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10